In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells

Cell Proliferation

Volumn 47, Issue 5, 2014, Pages 435-447

  Luca, T ^a   Barresi, V ^b,c   Privitera, G ^a   Musso, N ^b,c   Caruso, M ^d   Condorelli, D F ^b,c   Castorina, S ^a,b  

^a Fondazione Mediterranea GB Morgagni   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c SCUOLA SUPERIORE DI CATANIA   (Italy)

^d Istituto di Ricerca Medica Ed Ambientale   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANEUPLOIDY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CACO 2 CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL SUBPOPULATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG RECEPTOR BINDING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE NUMBER; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; COLONIC NEOPLASMS; DRUG EFFECTS; GENETICS; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CACO-2 CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; HCT116 CELLS; HT29 CELLS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84908606093     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12125     Document Type: Article

References (60)

1. Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S et al. (2010) Colon cancer. Crit. Rev. Oncol. Hematol. 74, 106-133.
2. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW et al. (2007) EUROCARE Working group: survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol. 8, 773-783.
3. Coleman MP, Gatta G, Verdecchia A, Estève J, Sant M, Storm H et al.; EUROCARE Working Group (2003) EUROCARE-3 summary cancer survival in Europe at the end of the 20th century. Ann. Oncol. 14(Suppl 5), v128-v149.
4. Gullick WJ (2001) The Type 1 growth factor receptors and their ligands considered as a complex system. Endocr. Relat. Cancer 8, 75-82.
5. Gullick WJ (2009) The epidermal growth factor system of ligands and receptors in cancer. Eur. J. Cancer 45(Suppl 1), 205-210.
6. Marmor MD, Skaria KB, Yarden Y (2004) Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 58, 903-913.
7. Lurje G, Lenz HJ (2009) EGFR signaling and drug discovery. Oncology 77, 400-410.
8. Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7(Suppl 4), 2-8.
9. Hubbard SR (2005) EGF receptor inhibition: attacks on multiple fronts. Cancer Cell 7, 287-288.
10. Wong SF (2005) Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin. Ther. 27, 684-694.
11. Scaltriti M, Baselga J (2006) The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 12, 5268-5272.
12. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3, 237-252.
13. Kuwada SK, Scaife CL, Kuang J, Li X, Wong RF, Florell SR et al. (2004) Effects of trastuzumab on epidermal growth factor receptor-dependent and-independent human colon cancer cells. Int. J. Cancer 109, 291-301.
14. Ross JS, McKenna BJ (2001) The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 19, 554-568.
15. Ismail HM, El-Baradie M, Moneer M, Khorshid O, Touny A (2007) Clinico-pathological and prognostic significance of p53, Bcl-2 and Her-2/neu protein markers in colorectal cancer using tissue microarray. J. Egypt. Natl. Canc. Inst. 19, 3-14.
16. Gill MK, Manjari M, Jain K, Kaur T (2011) Expression of Her-2/neu in colon carcinoma and its correlation with the histological grades and the lymph nodes status. JCDR 5, 1564-1568.
17. Kulig J, Kolodziejczyk P, Kulig P, Legutko J (2013) Targeted therapy for gastric cancer - current status. J. Oncol. Pharm. Pract. 19, 75-81.
18. Nathanson DR, Culliford AT 4th, Shia J, Chen B, D'Alessio M, Zeng ZS et al. (2003) HER 2/neu expression and gene amplification in colon cancer. Int. J. Cancer 105, 796-702.
19. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX et al. (2001) Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120, 1713-1719.
20. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345.
21. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F (2009) Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin. Exp. Immunol. 158, 1-9.
22. Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA et al. (2010) Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc. Natl. Acad. Sci. USA 107, 13252-13257.
23. Giannopoulou E, Antonacopoulou A, Floratou K, Papavassiliou AG, Kalofonos HP (2009) Dual targeting of EGFR and HER-2 in colon cancer cell lines. Cancer Chemother. Pharmacol. 63, 973-981.
24. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO J. 16, 1647-1655.
25. Grunwald V, Hidalgo M (2003) Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl. Cancer Inst. 95, 4851-4867.
26. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS et al. (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 102, 1915-1920.
27. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M (2009) Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc. Natl. Acad. Sci. USA 106, 3294-3299.
28. Fogh J, Fogh JM, Orfeo T (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59, 221-226.
29. Fortuna CG, Barresi V, Bonaccorso C, Consiglio G, Failla S, Trovato-Salinaro A et al. (2012) Design, synthesis and in vitro antitumour activity of new heteroaryl ethylenes. Eur. J. Med. Chem. 47, 221-227.
30. Luca T, Di Benedetto G, Scuderi MR, Palumbo M, Clementi S, Bernardini R et al. (2009) The CB1/CB2 receptor agonist WIN-55, 212-2 reduces viability of human Kaposi's sarcoma cells in vitro. Eur. J. Pharmacol. 616, 16-21.
31. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354.
32. Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 21, 177-184.
33. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR et al. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2-16.
34. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS (2003) Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer 10, 1-21.
35. Black JD, Brattain MG, Krishnamurthi SA, Dawson DM, Willson JK (2003) ErbB family targeting. Curr. Opin. Investig. Drugs 4, 1451-1454.
36. Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN et al. (2006) Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res. 66, 404-411.
37. Zhou Y, Brattain MG (2005) Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. Cancer Res. 65, 5848-5856.
38. Borg JP, Marchetto S, Le Bivic A, Ollendorff V, Jaulin-Bastard F, Saito H et al. (2000) ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2. Nat. Cell Biol. 2, 407-414.
39. Damstrup L, Kuwada SK, Dempsey PJ, Brown CL, Hawkey CJ, Poulsen HS et al. (1999) Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Br. J. Cancer 80, 1012-1019.
40. Kuwada SK, Li XF, Damstrup L, Dempsey PJ, Coffey RJ, Wiley HS (1999) The dynamic expression of the epidermal growth factor receptor and epidermal growth factor ligand family in a differentiating intestinal epithelial cell line. Growth Factors 17, 139-153.
41. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS et al. (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 68, 1953-1961.
42. Solmi R, Lauriola M, Francesconi M, Martini D, Voltattorni M, Ceccarelli C et al. (2008) Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. BMC Cancer 8, 227.
43. Bishop WP, Wen JT (1994) Regulation of Caco-2 cell proliferation by basolateral membrane epidermal growth factor receptors. Am. J. Physiol. 267, G892-G900.
44. Halter SA, Dempsey PJ, Matsui Y, Stokes MK, Graves-Deal R, Hogan BLM et al. (1992) Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-α. Characterization of mammary gland and skin proliferation. Am. J. Pathol. 140, 1131-1146.
45. Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A (2011) The multiple roles of amphiregulin in human cancer. Biochim. Biophys. Acta 1816, 119-131.
46. Johnson GR, Saeki T, Gordon AW, Shoyab M, Salomon DS, Stromberg K (1992) Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon. J. Cell Biol. 118, 741-751.
47. Culouscou JM, Remacle-Bonnet M, Carlton GW, Plowman GD, Shoyab M (1992) Colorectum cell-derived growth factor (CRDGF) is homologous to amphiregulin, a member of the epidermal growth factor family. Growth Factors 7, 195-205.
48. Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I et al. (2006) In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother. Pharmacol. 57, 709-718.
49. Grade M, Becker H, Liersch T, Ried T, Ghadimi BM (2006) Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact. Cell Oncol. 28, 71-84.
50. Castorina S, Barresi V, Luca T, Privitera G, Musso N, Capizzi C et al. (2010) Recent advances in molecular diagnostics of colorectal cancer by genomic arrays: proposal for a procedural shift in biological sampling and pathological report. Ital. J. Anat. Embryol. 115, 39-45.
51. Knutsen T, Padilla-Nash HM, Wangsa D, Barenboim-Stapleton L, Camps J, McNeil N et al. (2010) Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines. Genes Chromosom. Cancer 49, 204-223.
52. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7, 301-311.
53. Mandic R, Rodgarkia-Dara CJ, Zhu L, Folz BJ, Bette M, Weihe E et al. (2006) Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett. 580, 4793-5000.
54. Vokes EE, Chu E (2006) Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 20(5 Suppl 2), 15-25.
55. Harding J, Burtness B (2005) Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc.) 41, 107-127.
56. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A (2006) The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim. Biophys. Acta 1766, 120-139.
57. Klapper LN, Waterman H, Sela M, Yarden Y (2000) Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60, 3384-3388.
58. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K et al. (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28, 803-814.
59. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712.
60. Roepstorff K, Grandal MV, Henriksen L, Knudsen SL, Lerdrup M, Grøvdal L et al. (2009) Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 10, 1115-1127.